Identity
DHHB — INCI name diethylamino hydroxybenzoyl hexyl benzoate, marketed by BASF as Uvinul A Plus — is an oil-soluble organic UVA filter, designed on classical benzophenone chemistry and approved in Europe in 2005.
It exists for one reason: avobenzone's instability. Avobenzone has excellent long-UVA absorption and loses it rapidly under sunlight; DHHB was developed to occupy the same spectral territory without the same failure mode.
⚠️ Not to be confused with DHAB (diethylamino hydroxybenzoyl ascorbyl benzoate), a skin-bonding derivative appearing in related patent literature — a different substance.
How it works
DHHB absorbs with a peak at 354 nm, deep in the UVA-I range, with useful coverage across roughly 320-390 nm. Its contribution in UVB is minimal, so it is always paired with UVB filters — it is a specialist, not a broad-spectrum filter in the way bemotrizinol or zinc oxide are.
Its defining property is that its excited state resolves harmlessly. Where avobenzone's UV absorption drives a tautomeric shift that destroys its own UVA absorbance, DHHB returns to ground state without degrading — reported as photostable across all formulations in the published photochemical work, with no detectable UV-induced free radicals in filter mixtures. It also quenches singlet oxygen, which is relevant to reducing UV-induced oxidative stress rather than to UV filtering as such.
It binds skin very little — a bound proportion of about 3% in a skin-binding assay, against 76% for a comparator designed to bond — so it stays where it is applied.
The correction: DHHB does not stabilise avobenzone
This is the most useful thing in this entry, because the opposite is widely assumed. Since DHHB is photostable and avobenzone is not, and since both are UVA filters, it seems natural that pairing them would help. It does not.
Kawakami et al. (2017) tested this directly across multiple sunscreen formulations using HPLC and spectrophotometry. The result: DHHB did not present a photostabilising effect on avobenzone. Fluorescence spectroscopy explained why — the two interact by a static quenching mechanism, and DHHB does not affect avobenzone's excited-state lifetime. Förster resonance energy transfer, the mechanism usually responsible for singlet-singlet quenching, was judged unlikely in this system. In other words, DHHB never engages avobenzone's excited singlet state, which is the state that needs quenching.
The authors' conclusion followed directly: formulations containing DHHB alone should be considered more advantageous than those containing avobenzone, or avobenzone and DHHB together.
What DHHB does stabilise is the triazine filter class — a different interaction, and one reported positively in the photokinetics literature. Its lowest excited triplet state sits higher than those of octyl methoxycinnamate and octocrylene, so it can act as a triplet energy donor in mixtures. The stabilising ability is real; it simply does not extend to avobenzone.
The practical reading for anyone looking at an ingredient list: DHHB and avobenzone appearing together is not a photostability strategy. It may be a coverage decision, but the avobenzone in that formula still needs octocrylene, bemotrizinol or another genuine stabiliser to survive the day.
Reading the evidence honestly
Why grade A. Strong long-UVA absorption, genuine photostability, no phototoxic signal in the standard in vitro model, no detectable UV-induced free radicals, minimal skin binding, and two decades of European use. As a UVA filter it does its job without the caveat that dominates avobenzone's entry.
What the grade does not claim. DHHB is not broad-spectrum — it needs UVB partners, and a product is only as good as its whole filter system. Its safety file rests on SCCS assessment, not on the US maximal-use plasma programme, simply because it has never been through the FDA process; that is an absence of data rather than a concern, but it is an absence. And there is far less published work on it than on avobenzone or the mineral filters — it is a well-regarded filter with a moderate literature, not a heavily interrogated one.
The regulatory asymmetry is the practical story. DHHB has been standard in European, Australian, Japanese and Korean sunscreens for two decades while remaining unavailable in the United States. Bemotrizinol finally cleared the FDA in June 2026, after two decades pending; DHHB has not. That gap — not chemistry — is why American long-UVA protection has rested so heavily on avobenzone and zinc oxide.